169773-36-8

Basic information

• Product Name: 1-(2,4-dichlorophenyl)-2-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)ethanone
• Synonyms: 1-(2,4-dichlorophenyl)-2-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)ethanone
• CAS NO: 169773-36-8
• Molecular Formula: C12H11Cl2N3O
• Molecular Weight: 284.14124
• Mol File: 169773-36-8.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(2,4-dichlorophenyl)-2-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2,4-dichlorophenyl)-2-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)ethanone(169773-36-8)
• EPA Substance Registry System: 1-(2,4-dichlorophenyl)-2-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)ethanone(169773-36-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 169773-36-8(Hazardous Substances Data)

Usage

General Description

1-(2,4-dichlorophenyl)-2-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)ethanone is a chemical compound with the molecular formula C11H11Cl2N3O. It is a fungicide with broad-spectrum activity against various plant pathogens. The compound works by inhibiting the biosynthesis of ergosterol, an essential component of fungal cell membranes, leading to the disruption of fungal growth and reproduction. It is commonly used in agricultural settings to control fungal diseases in crops such as fruits, vegetables, and cereals. The compound is typically applied as a foliar spray or soil treatment to protect plants from diseases caused by fungi. Additionally, it has been tested for its potential use in controlling fungal infections in human and animal health.

Upstream product

• 541-73-1 1,3-Dichlorobenzene 
• 7343-34-2 3,5-dimethyl-1,2,4-triazole 
• 2631-72-3 2,4-dichlorophenacyl bromide 

Relevant articles and documents

Novel Tetrazole-Containing Analogues of Itraconazole as Potent Antiangiogenic Agents with Reduced Cytochrome P450 3A4 Inhibition

Itraconazole has been found to possess potent antiangiogenic activity, exhibiting promising antitumor activity in several human clinical studies. The wider use of itraconazole in the treatment of cancer, however, has been limited by its potent inhibition of the drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4). In an effort to eliminate the CYP3A4 inhibition while retaining its antiangiogenic activity, we designed and synthesized a series of derivatives in which the 1,2,4-triazole ring is replaced with various azoles and nonazoles. Among these analogues, 15n with tetrazole in place of 1,2,4-triazole exhibited optimal inhibition of human umbilical vein endothelial cell proliferation with an IC50 of 73 nM without a significant effect on CYP3A4 (EC50 > 20 μM). Similar to itraconazole, 15n induced Niemann-Pick C phenotype (NPC phenotype) and blocked AMPK/mechanistic target of rapamycin signaling. These results suggest that 15n is a promising angiogenesis inhibitor that can be used in combination with most other known anticancer drugs.